Haluk SAVAŞ, Gökay ALPAK, Gülçin ELBOĞA, Ahmet ÜNAL, Feridun BÜLBÜL

Agomelatin kullanımına bağlı gelişen karaciğer enzim yüksekliği

Majör depresyon psikiyatrik hastalıklar içinde en sık görülen hastalıklardan biridir. Klasik antidepresan tedaviler depresyonun tüm belirtilerini tedavi etmekte yetersiz kalabilmektedir. Bundan dolayı farklı mekanizmalarla etki eden antidepresan tedaviler geliştirilmeye başlanmıştır. Bu tedavilerden biride agomelatindir. Agomelatin melatonin hormonunun sentetik analoğu olan bir ilaçtır. Melatonin MT1 ve MT2 reseptörlerinin aktivitesini uyararak ve serotonin 5HT2C reseptör aktivitesini inhibe ederek etki gösterir. Agomelatin kullanan hastalarda karaciğer enzim yüksekliği açısından dikkatli olunması önerilmektedir. Bu olgu sunumunda agomelatin’e bağlı gelişen karaciğer enzim yüksekliği ve tedavi süreci sunulacaktır.

Anahtar Kelimeler:

agomelatin, karaciğer enzim yüksekliği, majör depresyon

Agomelatine-induced elevation of liver enzymes

Major depression is one of the most frequently seen psychiatric disorders. Classical antidepressant treatments might be insufficient in treating all symptoms of of depression. Therefore, antidepressant treatments which work through different mechanisms have been developed. One of these therapies is agomelatine. Agomelatine is a drug which is a synthetic analogue of melatonin hormone. Melatonin works by stimulating the activities of MT1 and MT2 receptors and inhibiting the activity of serotonin 5HT2C receptor. It is recommended to be cautious in patients taking agomelatine in terms of liver enzyme elevation. In this case report, agomelatine-induced elevation of liver enzymes and the treatment process will be presented.

Keywords:

agomelatine, elevated liver enzymes, major depression,

PDF

___

Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8:287-304.
Howland, Robert H, A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression. Drug Saf. 2011;34:709-31.
Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman Tancredi A, Pasteau V, Rivet JM, Cussac D. The novel melatonin agonist agomelatine (S20098) is anantagonist at 5-hydroxytryptamine 2c receptors, blockade of which enhances the activity of frontocorticaldopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954-64.
Kasper S, Hamon, M. Beyond the monoaminergic hypothesis:Agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry. 2009;10:117-26.
Howland, Robert H, A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression. Drug Saf. 2011;34:709-31.
Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebocontrolled Trial. J Clin Psychopharmacol. 2010;30:135-44.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, APA, 1994.
Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol. 2011;21:703-9.
Yüksel N. Genel Tıpta Antidepresan Kullanımı. Klinik Psikiyatri. 1999;4:7-25.
Persky S, Reinus JF. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig Dis Sci. 2003;4:939-44.
Feinberg SS. Correction of venlafaxine and duloxetine induced transaminase elevations with desvenlafaxine in a patient with Gilbert’s syndrome. CNS Spectr. 2010;15:53-5.
Hu KQ, Tiyyagura L, Kanel G, Redeker AG. Acute hepatitis induced by bupropion. Dig Dis Sci. 2000;45:1872-3.
Stuart AM. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol. 2006;16:633–8.